Verrica Pharmaceuticals Inc. (VRCA) — SEC Filings
Verrica Pharmaceuticals Inc. (VRCA) — 46 SEC filings. Latest: 8-K (Dec 30, 2025). Includes 32 8-K, 6 10-Q, 2 DEF 14A.
View Verrica Pharmaceuticals Inc. on SEC EDGAR
Overview
Verrica Pharmaceuticals Inc. (VRCA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 30, 2025: Verrica Pharmaceuticals Inc. announced on December 23, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its offic
Sentiment Summary
Across 46 filings, the sentiment breakdown is: 3 bearish, 41 neutral, 2 mixed. The dominant filing sentiment for Verrica Pharmaceuticals Inc. is neutral.
Filing Type Overview
Verrica Pharmaceuticals Inc. (VRCA) has filed 32 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13D/A, 2 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (46)
Risk Profile
Risk Assessment: Of VRCA's 41 recent filings, 4 were flagged as high-risk, 25 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $30,485,000 |
| Net Income | -$9,812,000 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $21,097,000 |
| Operating Margin | -16.4% |
| Total Assets | $40,896,000 |
| Total Debt | $34,077,000 |
Key Executives
- Jayson Rieger
- Ted White
- Paul B. Manning
- Dr. Paul L. Berns
- Dr. David J. Stark
- Mr. David M. S. Johnson
- Dr. Robert L. W. Smith
- Dr. Paul J. G. Mann
- Ms. Sarah E. Kelly
- Dr. Robert W. Buck
- Dr. Paul J. Hastings
- Mr. David R. Johnson
- Dr. Robert L. Armstrong
- Mark Prygocki
- Christopher G. Hayes
Industry Context
Verrica Pharmaceuticals operates in the dermatology therapeutics sector, focusing on prescription medications for skin diseases. The market for dermatology treatments is competitive, with established players and emerging biotechs. Key trends include the development of novel delivery systems and treatments for unmet medical needs, such as YCANTH for molluscum contagiosum.
Top Tags
financial-reporting (6) · executive-compensation (4) · material-definitive-agreement (4) · corporate-governance (4) · 10-Q (4) · management-change (4) · 8-K (3) · Pharmaceuticals (3) · corporate-action (3) · material-agreement (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue | $30.485M | Increased from $7.222M in 2024 for the nine months ended September 30, 2025 |
| Net Loss | $9.812M | Reduced from $60.377M in 2024 for the nine months ended September 30, 2025 |
| Cash and Cash Equivalents | $21.097M | Decreased from $46.329M at December 31, 2024 |
| Accumulated Deficit | $316.8M | As of September 30, 2025, indicating significant historical losses |
| Cash Used in Operating Activities | $13.036M | For the nine months ended September 30, 2025 |
| Net Loss Reduction | 83.7% | Percentage decrease in net loss from 2024 to 2025 for the nine-month period |
| Revenue Growth | 4x | Approximate multiple increase in total revenue from 2024 to 2025 for the nine-month period |
| Minimum Liquidity | $10.0M | Required by the Credit Agreement, a critical financial covenant |
| SEC File Number | 001-38529 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 46-3137900 | Company's tax identification number. |
| Product Revenue | $1.5M | Generated in Q2 2025, up from $0 in Q2 2024, indicating initial YCANTH market penetration. |
| R&D Expenses | $2.9M | Decreased from $5.3M in Q2 2024, reflecting a shift to commercialization. |
| SG&A Expenses | $12.3M | Increased from $10.9M in Q2 2024, driven by YCANTH commercialization efforts. |
| Potential Milestone Payments | $70.0M | From Torii Pharmaceutical Company Limited, offering future revenue potential. |
| Reporting Period End Date | 2025-03-31 | Indicates the financial period covered by the report. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Verrica Pharmaceuticals Inc. (VRCA)?
Verrica Pharmaceuticals Inc. has 46 recent SEC filings from Jan 2024 to Dec 2025, including 32 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of VRCA filings?
Across 46 filings, the sentiment breakdown is: 3 bearish, 41 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Verrica Pharmaceuticals Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Verrica Pharmaceuticals Inc. (VRCA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Verrica Pharmaceuticals Inc.?
Key financial highlights from Verrica Pharmaceuticals Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for VRCA?
The investment thesis for VRCA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Verrica Pharmaceuticals Inc.?
Key executives identified across Verrica Pharmaceuticals Inc.'s filings include Jayson Rieger, Ted White, Paul B. Manning, Dr. Paul L. Berns, Dr. David J. Stark and 10 others.
What are the main risk factors for Verrica Pharmaceuticals Inc. stock?
Of VRCA's 41 assessed filings, 4 were flagged high-risk, 25 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Verrica Pharmaceuticals Inc.?
Forward guidance and predictions for Verrica Pharmaceuticals Inc. are extracted from SEC filings as they are enriched.